Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Basit Öğe Kaydı
dc.authorscopusid55504930000
dc.authorscopusid57196215937
dc.authorscopusid56363716400
dc.authorscopusid6603382867
dc.authorscopusid26662691100
dc.authorscopusid8665552100
dc.authorscopusid55892938700
dc.contributor.authorKaplan, M.A.
dc.contributor.authorŞendur, M.A.N.
dc.contributor.authorCangır, A.K.
dc.contributor.authorFırat, P.
dc.contributor.authorGöker, E.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorOyan, B.
dc.date.accessioned2024-08-25T18:32:26Z
dc.date.available2024-08-25T18:32:26Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractPleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities. © 2023 The Author(s)en_US
dc.description.sponsorshipBristol-Myers Squibb, BMSen_US
dc.description.sponsorshipThis work was supported by Bristol Myers Squibb, Istanbul, Turkey .en_US
dc.identifier.doi10.1016/j.currproblcancer.2023.101017
dc.identifier.issn0147-0272
dc.identifier.scopus2-s2.0-85173875640en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.currproblcancer.2023.101017
dc.identifier.urihttps://hdl.handle.net/11454/100235
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofCurrent Problems in Canceren_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectBiomarkeren_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectImmune checkpoint inhibitoren_US
dc.subjectImmunotherapyen_US
dc.subjectPleural mesotheliomaen_US
dc.titleEstablished and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Groupen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu